iTrack™ Canaloplasty to be Featured at the 2023 Asia-Pacific Academy of Ophthalmology Congress (APAO)

California, USA, February 23, 2023 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to announce that the Company's proprietary iTrack™ family of canaloplasty devices will be featured during the official scientific program of the 38th Asia-Pacific Academy of Ophthalmology Congress (APAO), taking place on February 23-26, 2023, in Kuala Lumpur, Malaysia.

Nova Eye Medical will host a series of in-booth presentations to showcase the latest developments and advancements in canaloplasty, including the ***iTrack™ Advance***, the next generation of the canaloplasty device now available to surgeons, along with the earlier generation iTrack™ device.

These sessions will provide an opportunity to hear from leading surgeons about the impact and the future of glaucoma surgery.

A summary of the presentations and posters is included below.

Friday,
February 24, 2023
Location:
Exhibit #6041

Paul Singh, MD; Jason Cheng, MD
In-booth presentation
Time: 2:00 - 2:30 PM

Paul Singh, MD; Nathan Kerr, MD
In-booth presentation
Time: 4:00 - 4:30 PM

Saturday, **February 25, 2023** Location: Exhibit #6041	**Paul Singh, MD** **MIGS Wet Lab**, **hosted by Dave Patel, MD et al.** Time: 11:00 AM - 1:00 PM Location: Kuala Lumpur Convention Centre, **Paul Singh, MD; Joseph Panarelli, MD** In-booth presentation Time: 2:00 - 2:30 PM **Paul Singh, MD; Jason Cheng, MD** In-booth presentation Time: 4:00 - 4:30 PM
Poster	**Jason Cheng, MD** **"Safety and Efficacy of Ab-Interno Canaloplasty in Angle Closure Glaucoma: 12-Month Results"**

Nova Eye Medical will also be exhibiting at the APAO on February 23-26, 2023 from 8 AM - 5 PM at Kuala Lumpur Convention Centre, **exhibit #6041**.

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures, and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™, a consumable surgical device for the treatment of glaucoma. The Company also manufactures and sells the proprietary Molteno3® glaucoma drainage device for the treatment of severe or complex glaucoma. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia, and Berlin, Germany, and a global network of more than 50

distribution partners. Manufacturing facilities are located in Fremont, California, and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com

---

ABOUT CANALOPLASTY

First introduced in 2008, canaloplasty is a surgical treatment for glaucoma that targets the main sites of outflow resistance in the conventional outflow pathway: the trabecular meshwork, Schlemm's canal, and the distal collector channels. Based on the same principles as angioplasty, a flexible microcatheter is cannulated 360 degrees around Schlemm's canal during the procedure to manually break and remove blockages. Next, viscoelastic fluid is injected into Schlemm's canal as the microcatheter is withdrawn to dilate the distal outflow system and to improve the function of the trabecular meshwork.

ABOUT THE iTRACK™ PORTFOLIO

Nova Eye Medical (formerly iScience Interventional) pioneered the canaloplasty market with the launch of the world's first canaloplasty device, *iTrack*™, in 2008. Since then, more than 100,000 canaloplasty procedures have been performed with the *iTrack*™ device, cementing its role in the treatment of glaucoma both as a standalone procedure and in combination with cataract surgery. Launched in 2022, the *iTrack*™ *Advance* leverages the proprietary features of the original *iTrack*™ device but incorporates a new handheld injector design, which improves the overall surgical efficiency of the canaloplasty procedure.

iTrack™ Advance has a CE Mark (Conformité Européenne) for the treatment of open-angle glaucoma and is currently available in selected markets in Europe and the Asia Pacific. iTrack™ Advance is not available for use or sale in the USA. The iTrack™ Advance is indicated for fluid infusion and aspiration during surgery and for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma.

iTrack™ has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) 510(k) # K080067 for the treatment of open-angle glaucoma. The iTrack™ canaloplasty microcatheter has been cleared for the indication of fluid infusion and aspiration during surgery and for catheterization and

viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma. The iTrack™ canaloplasty microcatheter is currently not 510(k) cleared for use with the ab-interno technique in the United States.

For additional information about the iTrack™ portfolio, including safety information, please visit: www.glaucoma-iTrack.com

For additional information about *iTrack™ Advance*, including safety information, please visit https://itrack-advance.com/ or contact:

Kate Hunt: Nova Eye Chief Commercial Officer - khunt@nova-eye.com
Giorgio Pirazzini: GP Communications – giorgio@gpcommunications.eu